Table 1.
Detailed clinical characteristics of patients including cytogenetic and molecular genetic information.
| Training Set (n = 18) | Test Set (n = 114) | |
|---|---|---|
| Clinical data | ||
| Gender (male/female) | 12 (66%) / 6 (33%) | 53 (46%) / 61 (54%) |
| Age (y, median) | 50 | 44 |
| AML history | ||
| De novo | 15 (83%) | 100 (88%) |
| Secondary | 1 (6%) | 4 (4%) |
| Therapy related | 2 (11%) | 10 (8%) |
| WBC count (106/L, median) | 35 | 16 |
| Platelet count (106/L, median) | 45 | 64 |
| PB blast count (%, median) | 71 | 32 |
| BM blast count (%, median) | 80 | 75 |
| LDH count (U/L, median) | 562 | 442 |
| Response to induction therapy | ||
| Complete remission | 12 (66%) | 85 (75%) |
| Refractory disease | 6 (33%) | 24 (21%) |
| Early death | 0 (0%) | 5 (4%) |
| Outcome | ||
| OS (days, median) | 448 | 594 |
| EFS (days, median) | 234 | 224 |
| RFS (days, median) | 574 | 391 |
| Cytogenetic risk groups (ELN 2010) | ||
| Favorable | 9 (50%) | 38 (33%) |
| Intermediate-I | 3 (17%) | 37 (32%) |
| Intermediate-II | 3 (17%) | 17 (15%) |
| Unfavorable | 3 (17%) | 17 (15%) |
| NA | 0 (0%) | 5 (4%) |
Abbreviations: WBC, white blood cell count; BM, bone marrow; PB, peripheral blood; LDH, lactate dehydrogenase; OS, overall survival; EFS, event free survival; RFS, relapse free survival; NA, not available